Bookbuilding IPO | ₹[.] Cr | Listing at BSE SME |
Sai Primus Lifebiotech Ltd. has filed a Draft Red Herring Prospectus (DRHP) with the exchange on June 27, 2026 to raise funds through Initial Public Offer (IPO).
Sai Primus Lifebiotech Ltd. IPO is a Book Build Issue consisting solely of fresh issue of upto 0.45 crore equity shares.
The equity shares are proposed to be listed on the BSE SME. Socradamus Capital Pvt.Ltd. is the book running lead manager and Purva Sharegistry (India) Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Sai Primus Lifebiotech IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 45,00,000 shares (agg. up to ₹[.] Cr) |
| Fresh Issue | 45,00,000 shares (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 99,00,000 shares |
| Share Holding Post Issue | 1,44,00,000 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Sat, Jun 27, 2026 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Offer |
| NII Shares Offered | Not less than 15% of the Net Offer |
ncorporated in March 2017, Sai Primus Lifebiotech Limited is a pharmaceutical and nutraceutical Contract Development and Manufacturing Organization (CDMO) specializing in the manufacturing of oral solid dosage (OSD) formulations, including tablets and capsules. The company provides third-party contract manufacturing, private labelling, product development, regulatory support, and direct branding under its own "SPL" brand for domestic and international markets.
The company manufactures a wide range of pharmaceutical products across therapeutic segments such as anti-diabetics, anti-hypertensives, anti-infectives, and analgesics, along with nutraceutical products focused on immunity, wellness, bone health, liver health, and general nutrition. Its operations include formulation development, raw material sourcing, manufacturing, packaging, quality control, documentation, and exports. The manufacturing facility in Puducherry is supported by in-house R&D, Quality Assurance (QA), and Quality Control (QC) laboratories and holds WHO-GMP, FSSAI, HACCP, and multiple international regulatory approvals.
Since entering export markets in 2020, Sai Primus has expanded its portfolio to over 279 pharmaceutical and 170 nutraceutical products, serving customers through CDMO, private labelling, and direct branding models.
As of December 31, 2025, the company had a workforce of 444 personnel, comprising 195 permanent employees and 249 floating labourers supporting manufacturing and warehouse operations.
Strengths
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 75.38 | 68.82 | 37.59 | 38.55 |
| Total Income | 71.87 | 79.94 | 56.72 | 44.51 |
| Profit After Tax | 5.63 | 7.36 | 4.14 | 0.87 |
| EBITDA | 9.19 | 11.80 | 7.01 | 3.27 |
| NET Worth | 15.62 | 9.99 | 2.63 | -1.50 |
| Reserves and Surplus | 15.32 | 9.69 | 2.33 | -1.80 |
| Total Borrowing | 21.05 | 18.75 | 18.37 | 18.48 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹131.15 (-2.85%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹40.49 (+3.69%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.50 (+3.86%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹268.00 (+2.29%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹238.95 (-1.55%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹109.00 (+3.76%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹240.60 (-3.51%) |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹69.54 (-4.99%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹556.10 (-2.28%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,062.20 (+0.04%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,439.60 (+2.37%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹168.00 (+1.44%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.73 (-3.22%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards construction of the proposed corporate office and guest house of the company in Tamil Nadu, India | 4.79 |
| 2 | Funding capital expenditure towards procurement of machineries for expansion and upgradation of the existing manufacturing facility in Puducherry, India | 7.45 |
| 3 | Repayment and/or pre-payment, in full or in part, of certain outstanding borrowings availed by the company | 13.50 |
| 4 | Funding incremental working capital requirements; and | 19.50 |
| 5 | General Corporate Purposes | |
| Total | 45.25 |
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 58.63% | 116.73% |
| ROCE | 34.27% | 44.46% |
| Debt/Equity | 1.35 | 1.88 |
| RoNW | 43.97% | 116.73% |
| PAT Margin | 7.89% | 9.32% |
| EBITDA Margin | 12.88% | 14.94% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 7.44 | 5.21 |
| Promoter Holding | 84.70% |
Lead Manager Reports
Sai Primus Lifebiotech IPO is a SME IPO of 45,00,000 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Sai Primus Lifebiotech IPO open and close dates are not available as of now.
Purva Sharegistry (India) Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Sai Primus Lifebiotech IPO using UPI as a payment gateway. Zerodha customers can apply in Sai Primus Lifebiotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Sai Primus Lifebiotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Sai Primus Lifebiotech IPO dates are not announced. Please check back again after some time.
Sai Primus Lifebiotech IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Sai Primus Lifebiotech IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Sai Primus Lifebiotech IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Sai Primus Lifebiotech IPO allotment status.
The Sai Primus Lifebiotech IPO listing date is not yet announced. The tentative date of listing is .
